GLONGHUI, March 18 | CITIC Construction Investment Research Report indicates that the revenue of New Novus (300765.SZ) declined for the full year of 2023, mainly due to pressure on caffeine prices, but due to the further decline in raw material costs, increased product gross margin, and steady profit growth, the performance was in line with expectations. The company acquired Jushi Biotech and Shiyao Baike, a subsidiary of Shiyao Group, and introduced a number of innovative assets such as monoclonal antibodies, ADC, mRNA vaccines, and GLP-1. Among them, PD-1 monoclonal antibodies and omalizumab are expected to be approved and contribute revenue this year. The company accelerates the deployment of innovative pharmaceuticals and opens up room for future growth. Maintain a “buy” rating.
研报掘金丨中信建投：新诺威加速布局创新药领域，打开未来成长空间，维持“买入”评级
Research Nuggets丨CITIC Construction Investment: New Novartis accelerates the layout of innovative pharmaceuticals, opens up room for future growth, and maintains a “buy” rating
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.